Hubbry Logo
search button
Sign in
Atagabalin
Atagabalin
Comunity Hub
arrow-down
History
arrow-down
starMore
arrow-down
bob

Bob

Have a question related to this hub?

bob

Alice

Got something to say related to this hub?
Share it here.

#general is a chat channel to discuss anything related to the hub.
Hubbry Logo
search button
Sign in
Atagabalin
Community hub for the Wikipedia article
logoWikipedian hub
Welcome to the community hub built on top of the Atagabalin Wikipedia article. Here, you can discuss, collect, and organize anything related to Atagabalin. The purpose of the hub is to connect people, fos...
Add your contribution
Atagabalin
Atagabalin
Clinical data
ATC code
  • none
Identifiers
  • [(3S,4S)-1-(aminomethyl)-3,4-dimethylcyclopentyl]acetic acid
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC10H19NO2
Molar mass185.267 g·mol−1
3D model (JSmol)
  • C[C@H]1CC(C[C@@H]1C)(CC(=O)O)CN
  • InChI=1S/C10H19NO2/c1-7-3-10(6-11,4-8(7)2)5-9(12)13/h7-8H,3-6,11H2,1-2H3,(H,12,13)/t7-,8-/m0/s1 checkY
  • Key:IUVMAUQEZFTTFB-YUMQZZPRSA-N checkY
 ☒NcheckY (what is this?)  (verify)

Atagabalin (PD-0200,390) is a drug developed by Pfizer and related to gabapentin, which similarly binds to the α2δ calcium channels (1 and 2).[1] It was under development as a treatment for insomnia,[2][3][4] but was discontinued following unsatisfactory trial results.

See also

[edit]

References

[edit]
  1. ^ Blakemore DC, Bryans JS, Carnell P, Carr CL, Chessum NE, Field MJ, Kinsella N, Osborne SA, Warren AN, Williams SC (January 2010). "Synthesis and in vivo evaluation of bicyclic gababutins". Bioorganic & Medicinal Chemistry Letters. 20 (2): 461–4. doi:10.1016/j.bmcl.2009.11.118. PMID 20005103.
  2. ^ Corrigan B, Feltner DE, Ouellet D, Werth JL, Moton AE, Gibson G (August 2009). "Effect of renal impairment on the pharmacokinetics of PD 0200390, a novel ligand for the voltage-gated calcium channel alpha-2-delta subunit". British Journal of Clinical Pharmacology. 68 (2): 174–80. doi:10.1111/j.1365-2125.2009.03444.x. PMC 2767279. PMID 19694735.
  3. ^ Quintero JE, Pomerleau F, Huettl P, Johnson KW, Offord J, Gerhardt GA (May 2011). "Methodology for rapid measures of glutamate release in rat brain slices using ceramic-based microelectrode arrays: Basic characterization and drug pharmacology". Brain Research. 1401: 1–9. doi:10.1016/j.brainres.2011.05.025. PMC 3197737. PMID 21664606.
  4. ^ Kjellsson MC, Ouellet D, Corrigan B, Karlsson MO (June 2011). "Modeling Sleep Data for a New Drug in Development using Markov Mixed-Effects Models". Pharmaceutical Research. 28 (10): 2610–27. doi:10.1007/s11095-011-0490-x. PMID 21681607. S2CID 22241527.